Here is an update from Endo Pharmaceuticals on their research into the effectiveness of Pagoclone, a drug which was being studied to help treat stuttering:
Endo Pharmaceuticals has completed the initial analyses of the data from an ongoing pagoclone study (IP456-041). Although the study did not meet its pre-specified criteria for success, there were some trends of interest that Endo will look at more closely by conducting additional analyses of the data. The last part of this study will continue until completion late this year. A second active pagoclone study (IP456-039) will be closed in an orderly manner over the next several months. Patients participating in that study will be encouraged to discuss other treatment options with their physicians.
We are no longer enrolling any new patients or investigators to participate in pagoclone clinical studies.
For further questions, please call Endo Medical Information at 1-800-462-ENDO (3636).
(via Endo Pharmaceuticals)
